Welcome to GSK clinical study register

GSK’s long-standing commitment to clinical trial transparency

We recognize the importance of publicly disclosing clinical research on our products. In 2004 we introduced the GSK study register, a place where anyone can access information about the clinical research we carry out. We were the first pharmaceutical company to do this.​

Our clinical trial results are made public regardless of whether they are positive or negative. Before the trial begins, we publicly register the study protocol summary, which includes the trial’s objectives and design. Once the clinical trial has completed, we disclose a summary of the results, a plain language summary of results (for Phase 2-4 clinical trials only), redacted* version of the full study protocol, the statistical analysis plan and clinical trial report synopsis. We also list the clinical trials that are available for patient-level data sharing. Click here to find more information about our commitments.​

We disclose all studies that evaluate the clinical efficacy and/or safety or effectiveness of our medicines and vaccines. As part of our commitment to transparency of clinical research responsible business performance report 2024, we have made over 7,400 protocol summaries and over 6,500 results summaries available since the GSK study register was set up in 2004.

* Personal information and commercially confidential information